MB
DCPH

MPM BioImpact’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

MPM BioImpact’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-215,570
Closed -$13.4M – 12
2019
Q4 		$13.4M Buy
+215,570
New +$10.2M 4.75% 7

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

MPM BioImpact's DCPH Position: Q1 2020 in Review

MPM BioImpact sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2020, closing a stake of 215,570 shares — an estimated $13.4M sold.

MPM BioImpact first reported a position in DCPH in Q4 2019 and held it in 1 quarter. The position peaked at $13.4M in Q4 2019. 148 funds tracked by Wall St. Rank hold DCPH as of Q1 2020.

  • MPM BioImpact reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • MPM BioImpact sold 215,570 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $13.4M.
  • MPM BioImpact first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • MPM BioImpact's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $13.4M in Q4 2019.
  • 148 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on MPM BioImpact's 13F filing for Q1 2020, filed 13 May 2020.